# Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

> **NCT00613132** · PHASE1 · COMPLETED · sponsor: **Annick Desjardins** · enrollment: 78 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **DRUG:** Gleevec, RAD001, and Hydroxyurea

## Key facts

- **NCT ID:** NCT00613132
- **Lead sponsor:** Annick Desjardins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2008-08
- **Final completion:** 2013-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613132, "Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00613132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*